Eisai Innovation, Inc. is a strategic investment
organization aspiring to identify synergies between the
scientific community and the Eisai network of companies. Our
investment work aims to…

Help create a world free from
fear and pain of disease

Make predictions about future diseases and
consider sustainable development goals for

Acquire innovative

Lead Eisai into the top 10 health care
companies by collaborating with biotech and
digital health companies and through M&A.

Keep up with the latest

Cutting-edge technologies, drug
modalities and digital healthcare
solutions all enable Eisai to create a
near- and long-term term strategy.

Establish full-scale global
CVI (Corporate Venture
Investment) capability

Enable Eisai to take a leadership position
in supporting academic-established

Foster top talent

Translate newly obtained knowledge
into action.


goals icon


Strategic investment to create
synergy with Eisai’s business

size icon


140 M USD (15 B JPY)
1-5 M USD

regions icon


Global investment (US/Canada,
Europe, JP/China, Africa)

stage icon


Seed ~ mid-stage companies

target icon


Neurology & Oncology and their
digital solutions, Diagnostics

period icon


3-10 years for total investment

offices icon


Cambridge (Mass), San Francisco,




Yoshiharu Mizui

President of Eisai Innovation, Inc.

Yoshiharu Mizui founded Eisai Innovation, Inc. in 2019. Prior to that he was a global head of the BD/Strategy Department in Oncology Business Group at Eisai from 2016-2019. He was also a founding member of H3 Biomedicine and led the oncology program from 2011-2016. He has more than 20 years of experience as a discovery research biologist. He received his Ph.D. from Kyushu University.

Kou Qin, Ph.D.

Managing Director of Investment, Cambridge office

Kou Qin joined Eisai Innovation, Inc. in 2021. Previously at MSA Capital, he was in charge of healthcare strategy and investment globally. Prior to that, he ran the corporate incubation program at BGI. He started Skinome, a skin disease diagnosis company, invested by Y Combinator (YC) fellowship. He received his Ph.D. in neuroscience from the Medical College of Georgia, and Master of Science degree from the public health school of Harvard University.

Paul Wu, Ph.D.

Investment Principal, San Francisco office

Paul Wu joined Eisai Innovation, Inc in 2022. His professional background includes venture capital, strategic business development, and entrepreneurship. Most recently, he led early-stage investments at Grey Sky Venture Partners focusing on health, biotechnology, and digital companies. He earned his MBA from MIT Sloan and his Ph.D. in Biomedical Engineering from Northwestern University.


To find out more, please email us at info@eisaiinnovation.com.
Please include your name, organization, global location and a short message regarding your
interest. In the subject line, please indicate if this is regarding COLLABORATIONS, INVESTMENTS or

About Eisai: Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan, with
approximately 10,000 employees worldwide. We define our corporate mission as “giving first thought to patients and their
families and to increasing the benefits health care provides,” which we call our human health care (hhc) philosophy. We strive to
realize our hhc philosophy by delivering innovative products in therapeutic areas with high unmet medical needs, including
Oncology and Neurology. In the spirit of hhc, we take that commitment even further by applying our scientific expertise, clinical
capabilities and patient insights to discover and develop innovative solutions that help address society's toughest unmet needs,
including neglected tropical diseases and the Sustainable Development Goals.

For more information about Eisai, please visit www.eisai.com (for global), us.eisai.com (for U.S.) or www.eisai.eu (for Europe, Middle
East, Africa), and connect with us on X (U.S. and global) and LinkedIn (for U.S.).